Safety Monitoring in Clinical Trials

Pharmaceutics

Bin Yao¹  Li Zhu²  Qi Jiang² 

[1] Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA;

关键词: clinical trial;    safety monitoring;    Data and Safety Monitoring Board (DSMB);    sequential probability ratio test (SPRT);    Bayesian methods;   

DOI  :  10.3390/pharmaceutics5010094

来源: mdpi

【 摘 要 】

Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure a systematic approach to safety monitoring. The regulatory landscape has evolved with increased requirements for risk management plans, risk evaluation and minimization strategies. As the industry transitions from passive to active safety surveillance activities, there will be greater demand for more comprehensive and innovative approaches that apply quantitative methods to accumulating data from all sources, ranging from the discovery and preclinical through clinical and post-approval stages. Statistical methods, especially those based on the Bayesian framework, are important tools to help provide objectivity and rigor to the safety monitoring process.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.